Intravitreal dexamethasone for central retinal vein occlusion with low visual acuity: a retrospective study

2013 ◽  
Vol 97 (6) ◽  
pp. 796-797 ◽  
Author(s):  
Christiana Dinah ◽  
Kapka Nenova ◽  
Sreekumari Pushpoth ◽  
Ibraheem El-Ghrably ◽  
Deepali Varma ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Retrospective Study ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Vein Occlusion ◽  
Intravitreal Dexamethasone ◽  
Central Retinal Vein

scholarly journals Intravitreal Steroid Injections in Macular Edema due to Central Retinal Vein Occlusion

2019 ◽  
pp. 38-44
Keyword(s):  
Visual Acuity ◽  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Side Effect ◽  
Lamina Cribrosa ◽  
Initial Application ◽  
Vein Occlusion ◽  
Intravitreal Dexamethasone ◽  
Central Retinal Vein

Retinal vein occlusion is the most common retinal vascular disease after diabetic retinopathy. An occlusion that affects the entire retinal venous system at the level of the lamina cribrosa is called central retinal vein occlusion (CRVO). One of the major complications that threaten visual acuity in CRVO patients is macular edema. Intravitreal dexamethasone implant is widely used in the treatment of macular edema. Efficacy has been shown in terms of short-term edema resolution and increased visual acuity. It seems that the effect on the macula decreases on average in the third month. It is a good option for patients who need to reduce the number of visits. There is no additional side effect except an increase in the incidence of cataracts with recurrent injections. Increasing of intraocular pressure appears to be a tolerable side effect. Their activities are reduced when they are done every six months or when the initial application period is long. Intravitreal steroid treatment is an effective alternative for macular edema secondary to CRVO.

scholarly journals The Systemic and Ocular Risk Factors for Retinal Vein Occlusion: A Retrospective Study

2021 ◽  
Author(s):  
Jiacheng Ye ◽  
Min Zhou ◽  
Congyao Wang ◽  
Pengxia Wan
Keyword(s):  
Risk Factors ◽  
Visual Acuity ◽  
Retrospective Study ◽  
Endothelial Dysfunction ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Retinal Thickness ◽  
Low Vision ◽  
Vein Occlusion ◽  
Central Retinal Vein

Abstract BACKGROUND: We sought to evaluate the systemic and ocular risk factors for severity on visual acuity and central retinal thickness in macular edema secondary to retinal vein occlusion (RVO-ME). METHODS: This retrospective study included 46 RVO-ME patients in The First Affiliated Hospital of Sun Yat-sen University from January 2015 to November 2019. Systemic examinations include blood pressure, blood glucose, blood lipids, vascular endothelial function, and carotid artery color ultrasound. Ocular examinations include the best-corrected visual acuity (BCVA) and the central retinal thickness (CRT). The integrity of the outer retina was evaluated as well. According to the baseline BCVA and CRT levels, the patients were divided into high vision group and low vision group, high CRT group, and low CRT group. Multivariate logistic regression analyses were performed to analyze the risk factors on baseline BCVA and CRT.RESULTS: We enrolled 19 eyes of CRVO (central retinal vein occlusion) and 27 eyes of BRVO (branch retinal vein occlusion). We identified 31 (67.4%) as high CRT and 23 (50.0%) as poor VA of 46 patients on admission. There were 15 cases of BRVO in the high CRT group (48.4%) and 12 cases in the low CRT group (80.0%). The type of disease (BRVO/CRVO) was an independent factor of baseline CRT (P=0.017). Endothelial dysfunction correlates with baseline BCVA independently (P=0.038). Ellipsoidal zone (EZ) destruction was found in 19 cases (82.6%) in the low vision group and 6 cases (26.1%) in the high vision group. EZ integrity correlates with baseline BCVA independently (P=0.017). CONCLUSION: The central retinal vein occlusion (CRVO) has markedly higher CRT than branch retinal vein occlusion (BRVO). Endothelial dysfunction and disrupted ellipsoidal zone were significantly associated with poor baseline VA on admission.

scholarly journals Efficacy and Safety of an Aflibercept Treat-and-Extend Regimen in Treatment-Naïve Patients with Macular Oedema Secondary to Central Retinal Vein Occlusion (CRVO): A Prospective 12-Month, Single-Arm, Multicentre Trial

2018 ◽  
Vol 2018 ◽  
pp. 1-7
Author(s):  
Jose Garcia-Arumi ◽  
Francisco Gómez-Ulla ◽  
Navea Amparo ◽  
Enrique Cervera ◽  
Alex Fonollosa ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Macular Oedema ◽  
Efficacy And Safety ◽  
Foveal Thickness ◽  
Treat And Extend ◽  
Vein Occlusion ◽  
Treatment Naïve ◽  
Central Retinal Vein

Objectives. To evaluate efficacy and safety of an aflibercept treat-and-extend (TAE) regimen in patients with macular oedema (MO) secondary to central retinal vein occlusion (CRVO). Design, Setting, and Patients. Phase IV, prospective, open-label, single-arm trial in 11 Spanish hospitals. Treatment-naïve patients with <6 month diagnosis of MO secondary to CRVO and best-corrected visual acuity (BCVA) of 73-24 ETDRS letters were included between 23 January 2015 and 17 March 2016. Intervention. Intravitreal aflibercept 2 mg monthly (3 months) followed by proactive individualized dosing. Main Outcomes. Mean change in BCVA after 12 months. Results. 24 eyes (24 patients) were included; mean (SD) age: 62.8 (15.0) years; 54.2% male; median (IQR) time since diagnosis: 7.6 (3.0, 15.2) days. Mean BCVA scores significantly improved between baseline (56.0 (16.5)) and Month 12 (74.1 (17.6)); mean (95% CI) change: 14.8 (8.2, 21.4); P=0.0001. Twelve (50.0%) patients gained ≥15 ETDRS letters. Foveal thickness improved between baseline (mean: 569.4 (216.8) µm) and Month 12 (mean 257.4 (48.4) µm); P<0.0001. At Month 12, 8.3% patients had MO. The mean (SD) number of injections: 8.3 (3.0). No treatment-related AEs were reported. Five (20.8%) patients experienced ocular AEs. Two nonocular serious AEs were reported. Conclusions. An aflibercept TAE regimen improves visual acuity in patients with MO secondary to CRVO over 12 months with good tolerability.

scholarly journals Frosted Branch Angiitis Secondary to Familial Mediterranean Fever Resembling Central Retinal Vein Occlusion

2016 ◽  
Vol 2016 ◽  
pp. 1-4 ◽  
Author(s):  
Serdar Ozates ◽  
Pınar Çakar Ozdal ◽  
Mehmet Yasin Teke
Keyword(s):  
Visual Acuity ◽  
Familial Mediterranean Fever ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Vision Loss ◽  
Retinal Vasculitis ◽  
Frosted Branch Angiitis ◽  
Vein Occlusion ◽  
Mediterranean Fever ◽  
Central Retinal Vein

Purpose. To report a case of unilateral frosted branch angiitis (FBA) resembling central retinal vein occlusion associated with Familial Mediterranean Fever (FMF). Case Report. A 32-year-old woman presented with progressive, painless vision loss in her left eye lasting for 2 days. She was clinically diagnosed with FMF 2 months ago. The best-corrected visual acuity (BCVA) was 20/20 in her right eye and there was light perception in the left. Ophthalmologic examination revealed severe retinal vasculitis showing clinical features of FBA in the left eye. 64 mg/day oral methylprednisolone was started. A significant improvement in retinal vasculitis was observed in two weeks. However, BCVA did not increase significantly due to subhyaloid premacular hemorrhage. Argon laser posterior hyaloidotomy was performed. One week after hyaloidotomy, visual acuity improved to 20/20 and intravitreal hemorrhage disappeared. Four months after the first attack, FBA recurred. Oral methylprednisolone dosage was increased to 64 mg/day and combined with azathioprine 150 mg. At the end of 12-month follow-up, the BCVA was 20/25 and development of epiretinal membrane was observed in the left eye. Conclusions. Frosted branch angiitis may occur with gene abnormalities as an underlying condition. Our case showed that FMF might be a causative disease.

scholarly journals Central retinal vein occlusion: A patient with systemic sclerosis

2016 ◽  
Vol 73 (9) ◽  
pp. 868-872
Author(s):  
Jelena Karadzic ◽  
Aleksandra Radosavljevic ◽  
Igor Kovacevic
Keyword(s):  
Visual Acuity ◽  
Systemic Sclerosis ◽  
Macular Edema ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Case Reports ◽  
Immunosuppressive Treatment ◽  
Central Vein ◽  
Vein Occlusion ◽  
Central Retinal Vein

Introduction. Scleroderma (systemic sclerosis) is a severe chronic connective tissue disease, which results in involvement of numerous internal organs. Changes in the eye are the consequences of organ-specific manifestations of scleroderma or adverse effects of immunosuppressive treatment applied. Case report. We reported a 42-year-old woman with systemic sclerosis and acute deterioration of vision in the left eye, with visual acuity 0.9. After thorough clinical examination, including fluorescein angiography and optical coherence tomography, the diagnosis of nonischemic central retinal vein occlusion was made. Further biochemical, rheumatological and immunological investigation, apart from inactive systemic sclerosis, showed normal findings. Therefore, the cause of central retinal vein occlusion could only be attributed to the microvascular changes in systemic sclerosis. After three months, visual acuity deteriorated to 0.6 due to the development of cystoid macular edema. The patient received intravitreal injection of bevacizumab and after a single dose visual acuity improved to 0.9. After a 6- month follow-up, macular edema resolved and visual acuity stabilized. Conclusion. According to our knowledge and current data from the literature, central retinal vein occlusion is a rare vision threatening manifestation of scleroderma. There are only few published case reports on central vein occlusion in scleroderma patients. Examination of the ocular fundus is recommended for evaluation of vascular disease in patients with systemic sclerosis.

Sign in / Sign up

Export Citation Format

Share Document